ATP5MK and metabolic syndrome: Research indicates that AGP is more stable and predictive of future CVD risks, such as hypertension and metabolic syndrome in young individuals, than hs-CRP (48), while a review study supports that biomarkers such as GlycA and GlycB could be superior for early detection and prediction of cardiometabolic diseases and inflammation (49).